List of Bridion drug patents

Bridion is owned by Organon Sub Merck.

Bridion contains Sugammadex Sodium.

Bridion has a total of 1 drug patent out of which 0 drug patents have expired.

Bridion was authorised for market use on 15 December, 2015.

Bridion is available in solution;intravenous dosage forms.

Bridion can be used as reversal of drug-induced neuromuscular block.

The generics of Bridion are possible to be released after 27 January, 2026.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44733 ORGANON SUB MERCK 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block
Jan, 2026

(2 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jun 25, 2024
M Jun 9, 2023

Drugs and Companies using SUGAMMADEX SODIUM ingredient

Market Authorisation Date: 15 December, 2015

Treatment: Reversal of drug-induced neuromuscular block

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of BRIDION before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in